NovoCure Ltd

NovoCure Ltd

NVCR

Get informed when a big investor buys or sells

+ Follow
Market Cap$1.79B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
NovoCure LtdNovoCure Ltd-10.1--52%3.40.7
$46.00

Target Price by Analysts

167.4% upsideNovoCure Target Price DetailsTarget Price
$-8.86

Current Fair Value

151.5% downside

Overvalued by 151.5% based on the discounted cash flow analysis.

Share Statistics

Market cap$1.79 Billion
Enterprise Value$1.92 Billion
Dividend Yield$- (-)
Earnings per Share$-1.22
Beta0.92
Outstanding Shares114,149,838

Return

Return on Equity-52.32%ROE
Return on Assets-21.96%
Return on Invested Capital-32.25%

Valuation & Multiples

P/E Ratio-10.08P/E Ratio
PEG-9.4PEG
Price to Sales3.44Price to Sales
Price to Book Ratio8.6Price to Book Ratio
Enterprise Value to Revenue2.85
Enterprise Value to EBIT-10.47
Enterprise Value to Net Income-12
Total Debt to Enterprise0.12
Debt to Equity0.71Debt to Equity

Revenue Sources

No data

Insider Trades

Last Earnings Call

Report Date
April 30, 2026
EPS Estimate
$-0.51
Average shareholder expectation
Revenue Estimate
$167.77 M
Average shareholder expectation

Next Earnings Call

Expected Date
July 23, 2026
EPS Estimate
$-0.30
Average shareholder expectation
Revenue Estimate
$172.72 M
Average shareholder expectation

Institutional Put/Call Ratio

Market sentiment based on institutional option activity.

Put/Call Ratio0.7442 39.69%
Total Calls930,900 13.15%
Total Puts692,800 86.09%

Institutional Ownership

Holdings and activity of institutional investors.

Ownership %88.71% 3.35%
Total Invested$1.08B 12.80%
Investors Holding231 15.00%

ESG Score

No data

About NovoCure Ltd

CEO: Asaf Danziger